.
MergerLinks Header Logo

Announced

Completed

Qualigen completed the merger with Ritter Pharmaceuticals.

Financials

Edit Data
Transaction Value-
Consideration TypeOrdinary Shares
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Friendly

Majority

Single Bidder

treatment development

Acquisition

Merger

United States

Public

Pharmaceuticals

Completed

Reverse Takeover

Synopsis

Edit

Qualigen, a privately-held company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases, completed the merger with Ritter Pharmaceuticals, which develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, in an all-stock deal. "The time is right for us to take advantage of our core science and regulatory experience from our diagnostic business and expand into promising cancer therapeutic drugs and devices. With this transaction and our key knowledge in cancer and infectious disease, we look forward to progressing our clinical development programs," Michael S. Poirier, President, Qualigen CEO and Chairman.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US